Danielle Frodyma

Mrs. Danielle Frodyma

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BNBeth K Neilsen
Beth K Neilsen
DFDanielle Frodyma
Danielle Frodyma
JMJamie L McCall
Jamie L McCall
KFKurt W Fisher
Kurt W Fisher
RLRobert E. Lewis
Robert E. Lewis
The cell cycle is under circadian regulation. Oncogenes can dysregulate circadian-regulated genes to disrupt the cell cycle, promoting tumor cell proliferation. As a regulator of G2/M arrest in response to DNA damage, the circadian gene Timeless Circadian Clock (TIMELESS) coordinates this connection and is a potential locus for oncogenic manipulation. TIMELESS expression was evaluated using RNASeq data from TCGA and by RT-qPCR and western blot analysis in a panel of colon cancer cell lines. TIMELESS expression following ERK inhibition was examined via western blot. Cell metabolic capacity, propidium iodide, and CFSE staining were used to evaluate the effect of TIMELESS depletion on colon cancer cell survival and proliferation. Cell metabolic capacity following TIMELESS depletion in combination with Wee1 or CHK1 inhibition was assessed. TIMELESS is overexpressed in cancer and required for increased cancer cell proliferation. ERK activation promotes TIMELESS expression. TIMELESS depletion increases γH2AX, a marker of DNA damage, and triggers G2/M arrest via increased CHK1 and CDK1 phosphorylation. TIMELESS depletion in combination with Wee1 or CHK1 inhibition causes an additive decrease in cancer cell metabolic capacity with limited effects in non-transformed human colon epithelial cells. The data show that ERK activation contributes to the overexpression of TIMELESS in cancer. Depletion of TIMELESS increases γH2AX and causes G2/M arrest, limiting cell proliferation. These results demonstrate a role for TIMELESS in cancer and encourage further examination of the link between circadian rhythm dysregulation and cancer cell proliferation.

27 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Chaitra RaoChaitra Rao
Chaitra Rao
Dianna HuismanDianna Huisman
Dianna Huisman
HVHeidi M. Vieira
Heidi M. Vieira
DFDanielle Frodyma
Danielle Frodyma
Beth NeilsenBeth Neilsen
Beth Neilsen
RLRobert E. Lewis
Robert E. Lewis
Genome-wide, loss-of-function screening can be used to identify novel vulnerabilities upon which specific tumor cells depend for survival. Functional Signature Ontology (FUSION) is a gene expression-based high-throughput screening (GE-HTS) method that allows researchers to identify functionally similar proteins, small molecules, and microRNA mimics, revealing novel therapeutic targets. FUSION uses cell-based high-throughput screening and computational analysis to match gene expression signatures produced by natural products to those produced by small interfering RNA (siRNA) and synthetic microRNA libraries to identify putative protein targets and mechanisms of action (MoA) for several previously undescribed natural products. We have used FUSION to screen for functional analogues to Kinase suppressor of Ras 1 (KSR1), a scaffold protein downstream of Ras in the Raf-MEK-ERK kinase cascade, and biologically validated several proteins with functional similarity to KSR1. FUSION incorporates bioinformatics analysis that may offer higher resolution of the endpoint readout than other screens which utilize Boolean outputs regarding a single pathway activation (i.e., synthetic lethal and cell proliferation). Challenges associated with FUSION and other high-content genome-wide screens include variation, batch effects, and controlling for potential off-target effects. In this review, we discuss the efficacy of FUSION to identify novel inhibitors and oncogene-induced changes that may be cancer cell-specific as well as several potential pitfalls within FUSION and best practices to avoid them.

10 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
Dianna HuismanDianna Huisman
Dianna Huisman
DCDeepan Chatterjee
Deepan Chatterjee
RSRobert A. Svoboda
Robert A. Svoboda
HVHeidi M. Vieira
Heidi M. Vieira
AIAbbie S. Ireland
Abbie S. Ireland
RLRobert E. Lewis
Robert E. Lewis
Small cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. In this study, we show that kinase suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor–propagating cell function and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of SCLC-A tumors and a potential subtype-specific therapeutic target. Implications: Manipulation of the molecular scaffold KSR2 in SCLC-A cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.

20 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DFDanielle Frodyma
Danielle Frodyma
TTThomas C. Troia
Thomas C. Troia
Chaitra RaoChaitra Rao
Chaitra Rao
RSRobert A. Svoboda
Robert A. Svoboda
JBJordan A. Berg
Jordan A. Berg
KFKurt Fisher
Kurt Fisher
Previous studies have shown that Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Beta (PGC-1β) and Estrogen-Related Receptor Alpha (ERRα) are over-expressed in colorectal cancer and promote tumor survival. In this study, we show that amino acid motif LRELL on PGC-1β is responsible for the physical interaction with ERRα and promotes ERRα mRNA and protein expression. We used RNAsequencing to determine the genes regulated by both PGC-1β & ERRα and found that mitochondrial Phosphoenolpyruvate Carboxykinase 2 (PCK2) was the gene that decreased most significantly after depletion of both genes. Depletion of PCK2 in colorectal cancer cells was sufficient to reduce anchorage-independent growth and inhibit glutamine utilization by the TCA cycle. Lastly, shRNA-mediated depletion of ERRα decreased anchorage-independent growth and glutamine metabolism, which could not be rescued by plasmid derived expression of PCK2. These findings suggest that transcriptional control of PCK2 is one mechanism used by PGC-1β and ERRα to promote glutamine metabolism and colorectal cancer cell survival.

2 July 2025
Verified
Other
Open access
Dianna HuismanDianna Huisman
Dianna Huisman
DCDeepan Chatterjee
Deepan Chatterjee
RSRobert A. Svoboda
Robert A. Svoboda
HVHeidi M. Vieira
Heidi M. Vieira
AIAbbie S. Ireland
Abbie S. Ireland
RLRobert E. Lewis
Robert E. Lewis
Figure S1. Sorting of CD24highCD44lowEPCAMhigh tumor propagating cells.

2 July 2025
Verified
Other
Open access
Dianna HuismanDianna Huisman
Dianna Huisman
DCDeepan Chatterjee
Deepan Chatterjee
RSRobert A. Svoboda
Robert A. Svoboda
HVHeidi M. Vieira
Heidi M. Vieira
AIAbbie S. Ireland
Abbie S. Ireland
RLRobert E. Lewis
Robert E. Lewis
Table S2. KSR2 is preferentially expressed in human SCLC-A cell lines.